09:01 AM EDT, 08/21/2025 (MT Newswires) -- Dynavax Technologies ( DVAX ) said Thursday that topline data from part 1 of its phase 1/2 study of its shingles vaccine candidate Z-1018 showed antibody and cellular immune response rates "similar" to GSK's (GSK) licensed Shingrix vaccine at one month after the second dose.

The vaccine was well-tolerated, with no safety concerns observed in the study in patients aged 50 to 69 years, Dynavax ( DVAX ) said.

At the dose regimen chosen for part 2 of the study, Dynavax ( DVAX ) said its investigational vaccine achieved a 100% humoral vaccine response rate compared with 96.9% for Shingrix, and an 89.7% cellular immune response rate compared with 93.5% for Shingrix, leading to a composite vaccine response rate of 89.7% for Z-1018 compared with 90.3% for Shingrix.

The company said it intends to advance Z-1018 into part 2 of the study in adults 70 years and older, with trials expected to begin in the second half of 2025.

Dynavax ( DVAX ) shares were up more than 7% in recent premarket activity Thursday.